Cosyntropin regulatory status
Current status of Cosyntropin in the United States: FDA approved. In sport: WADA prohibited. Details, sources, and the dated timeline follow.
By the PeptideAgent Editorial Team. Draft, pending editorial review. Last verified
What is the current status of Cosyntropin?
Regulatory: FDA approvedWADA: WADA prohibitedVerified: Verified Sep 23, 2026
- FDA and compounding
- FDA approved diagnostic drug (Cortrosyn, approved 1970; generics available). It is a diagnostic agent, not a therapy, so there is no compounding or telehealth market and it is not on any 503A bulks list. Not sold as a research chemical for human use in any meaningful volume.
- WADA
- WADA prohibited
- Access path
- Administered by a clinician in an endocrinology clinic, hospital, or lab as part of an ACTH stimulation test.
- Not dispensed to patients and not available through compounding pharmacies or telehealth.
Full Cosyntropin page: evidence, dosing in the literature, and sources
How has the status of Cosyntropin changed over time?
No dated regulatory event has been recorded for Cosyntropin. That usually means no FDA, PCAC, Federal Register, or WADA action has named it specifically. Category-wide actions are listed on the tracker hub.
Sources
Numbered citations in the answers above point here, followed by the regulatory sources on record for Cosyntropin and the source of each dated event.